May-10-22 07:15AM | |
06:00AM | |
May-06-22 09:59AM | |
May-03-22 06:00AM | |
May-02-22 06:00AM | |
Apr-27-22 05:25PM | |
Apr-06-22 06:00AM | |
Mar-17-22 01:54PM | |
Mar-15-22 08:48AM | |
07:15AM | |
06:00AM | |
05:55AM | |
Mar-14-22 06:00AM | |
Mar-10-22 05:55PM | |
Mar-08-22 06:00AM | |
Mar-01-22 05:55PM | |
06:00AM | |
Feb-24-22 08:35AM | |
Feb-15-22 08:22AM | |
Feb-14-22 09:49AM | |
Feb-01-22 06:00AM | |
Jan-31-22 06:51AM | |
06:00AM | |
Jan-10-22 06:00AM | |
Jan-05-22 06:00AM | |
Jan-04-22 06:00AM | |
Jan-03-22 06:00AM | |
Dec-21-21 01:38AM | |
Dec-07-21 07:00AM | |
Nov-30-21 06:00AM | |
Nov-29-21 06:00AM | |
Nov-15-21 08:44AM | |
06:01AM | |
Nov-04-21 03:01PM | |
Nov-01-21 06:00AM | |
Oct-18-21 06:00AM | |
Sep-10-21 04:57PM | |
Aug-30-21 06:00AM | |
Aug-16-21 08:26AM | |
Aug-10-21 07:15AM | |
06:00AM | |
Aug-02-21 06:00AM | |
Jul-12-21 04:11PM | |
Jul-08-21 06:39AM | |
Jul-07-21 09:29PM | |
08:01AM | |
Jul-06-21 04:01PM | |
Jun-28-21 06:00AM | |
May-24-21 06:01AM | |
May-16-21 05:21AM | |
May-10-21 07:30AM | |
06:00AM | |
06:00AM | |
May-06-21 06:00AM | |
Apr-19-21 06:00AM | |
Apr-18-21 08:30AM | |
Apr-16-21 06:00AM | |
Apr-15-21 04:01PM | |
06:00AM | |
Mar-23-21 10:24AM | |
07:30AM | |
06:05AM | |
06:05AM | |
Mar-11-21 06:00AM | |
Mar-01-21 06:00AM | |
Feb-22-21 06:00AM | |
Feb-17-21 06:00AM | |
Feb-15-21 01:12AM | |
Feb-08-21 06:00AM | |
Feb-01-21 06:00AM | |
Jan-19-21 06:00AM | |
Jan-11-21 06:00AM | |
Jan-05-21 06:00AM | |
Jan-04-21 06:00AM | |
Dec-14-20 06:00AM | |
Dec-11-20 10:23PM | |
Dec-08-20 12:43PM | |
Nov-16-20 11:19PM | |
Nov-15-20 08:50AM | |
Nov-12-20 06:00AM | |
Nov-02-20 06:00AM | |
Oct-22-20 06:00AM | |
Sep-24-20 08:15AM | |
06:00AM | |
Sep-04-20 12:52PM | |
Sep-02-20 06:21PM | |
Aug-31-20 06:00AM | |
Aug-19-20 01:33PM | |
Aug-12-20 07:30AM | |
06:00AM | |
Aug-07-20 08:33AM | |
Aug-05-20 04:21PM | |
Aug-04-20 06:00AM | |
Jul-16-20 06:00AM | |
Jul-14-20 06:00AM | |
Jul-09-20 06:00AM | |
Jun-30-20 06:00AM | |
Jun-22-20 04:35PM | |
Jun-17-20 09:34PM | |
09:53AM | |
|
|
|
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Dillon Michael P. | SVP, Chief Scientific Officer | Oct 04 | Option Exercise | 11.08 | 1,500 | 16,620 | 80,289 | Oct 07 04:11 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Oct 04 | Sale | 26.36 | 1,500 | 39,545 | 78,789 | Oct 07 04:11 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Sep 08 | Option Exercise | 6.87 | 11,384 | 78,264 | 90,173 | Sep 09 07:24 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Sep 08 | Sale | 27.42 | 11,384 | 312,093 | 78,789 | Sep 09 07:24 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Sep 07 | Option Exercise | 4.31 | 116 | 500 | 78,905 | Sep 09 07:24 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Sep 07 | Sale | 27.46 | 116 | 3,185 | 78,789 | Sep 09 07:24 PM | Stone Paul A. | SVP, Chief Financial Officer | Sep 07 | Sale | 27.42 | 2,500 | 68,542 | 12,944 | Sep 09 05:41 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Sep 02 | Sale | 25.09 | 10,000 | 250,943 | 78,789 | Sep 07 06:48 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Aug 09 | Option Exercise | 4.31 | 1,500 | 6,465 | 100,289 | Aug 11 05:19 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Aug 09 | Sale | 22.98 | 11,500 | 264,269 | 88,789 | Aug 11 05:19 PM | Throne Jason | SVP, General Counsel | Jul 27 | Option Exercise | 13.34 | 10,000 | 133,400 | 10,000 | Jul 29 05:17 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jul 27 | Option Exercise | 5.62 | 10,000 | 56,150 | 108,789 | Jul 29 05:18 PM | Throne Jason | SVP, General Counsel | Jul 27 | Sale | 25.17 | 10,000 | 251,683 | 0 | Jul 29 05:17 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jul 27 | Sale | 25.15 | 10,000 | 251,460 | 98,789 | Jul 29 05:18 PM | Throne Jason | SVP, General Counsel | Jul 06 | Option Exercise | 8.52 | 10,000 | 85,229 | 10,000 | Jul 08 07:00 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jul 06 | Option Exercise | 6.92 | 1,500 | 10,380 | 100,289 | Jul 08 07:01 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jul 06 | Sale | 22.24 | 1,500 | 33,358 | 98,789 | Jul 08 07:01 PM | Throne Jason | SVP, General Counsel | Jul 06 | Sale | 22.24 | 10,000 | 222,408 | 0 | Jul 08 07:00 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jun 17 | Option Exercise | 6.92 | 3,893 | 26,940 | 102,682 | Jun 17 08:59 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jun 17 | Sale | 22.49 | 3,893 | 87,540 | 98,789 | Jun 17 08:59 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jun 16 | Option Exercise | 6.92 | 1,107 | 7,660 | 99,896 | Jun 17 08:59 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jun 16 | Sale | 22.47 | 1,107 | 24,873 | 98,789 | Jun 17 08:59 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jun 07 | Option Exercise | 6.92 | 1,500 | 10,380 | 100,289 | Jun 09 06:12 PM | Dillon Michael P. | SVP, Chief Scientific Officer | Jun 07 | Sale | 20.22 | 1,500 | 30,333 | 98,789 | Jun 09 06:12 PM |
|